Scarica l'app Stockscreener
2.71
1.50%
0.04
Dopo l'orario di chiusura:
2.64
-0.07
-2.58%
OncoCyte Corporation Borsa (OCX) Ultime notizie
Seasoned Financial executive joins Oncocyte as CFO - Reuters
PURA VIDA INVESTMENTS, LLC Expands Stake in OncoCyte Corp - GuruFocus.com
OncoCyte stock maintains Buy rating with Needham after GraftAssure RUO launch - Investing.com
OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Earnings Call Transcript - Insider Monkey
OncoCyte: Q3 Earnings Snapshot - Darien Times
OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress i - GuruFocus.com
OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ... - Yahoo Finance
OncoCyte Corp Reports Q3 2024 Earnings and Strategic Updates - TipRanks
OncoCyte Corp (OCX) Q3 2024 Earnings: EPS of -$0.98 Misses Estimates, Revenue Falls Short at $115,000 - GuruFocus.com
Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 - The Manila Times
Oncocyte Corporation (OCX) Quarterly 10-Q Report - Quartz
What to Expect from OncoCyte's Earnings - Benzinga
Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 - ForexTV.com
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - MarketBeat
StockNews.com Initiates Coverage on OncoCyte (NASDAQ:OCX) - MarketBeat
Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles - The Manila Times
Oncocyte Corp expands equity incentive plan - Investing.com India
Oncocyte Corp expands equity incentive plan By Investing.com - Investing.com Australia
OncoCyte shares maintain Buy rating from Needham By Investing.com - Investing.com Nigeria
OncoCyte shares maintain Buy rating from Needham - Investing.com
OncoCyte Corp (OCX) Q2 2024 Earnings Call Highlights: Strategic Advances Amidst Financial Challenges - Yahoo Finance
Oncocyte reports breakthrough in breast cancer diagnostics - Investing.com
Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - The Manila Times
Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial - StockTitan
Broadwood Partners L.P. buys Oncocyte shares for $3.88 million By Investing.com - Investing.com Australia
Oncocyte CFO acquires $99,999 worth of company shares By Investing.com - Investing.com South Africa
Oncocyte CFO acquires $99,999 worth of company shares - Investing.com
Broadwood Partners L.P. buys Oncocyte shares for $3.88 million - Investing.com
OncoCyte Secures Funding Through Private Share Sale - Yahoo Finance
OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc. - Marketscreener.com
LENSAR reports inducement grants - Medical Buyer
Oncocyte Corporation enters into securities purchase agreement - Medical Buyer
Oncocyte Signs Leading Transplant Centers in US and Germany - The Manila Times
Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules - ForexTV.com
Sandfire Resources America Inc. Announces Incentive Plan Grants - The Manila Times
1.89%
2.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):